A Phase 1b/2a Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)
Latest Information Update: 01 Jun 2026
At a glance
- Drugs EN 001 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- Sponsors ENCell
Most Recent Events
- 26 May 2026 The protocol has been amended to addition in therapeutic endpoint and addition in in treatment arm size with change in study phase.
- 26 May 2026 Planned number of patients changed from 12 to 27.
- 26 May 2026 Planned End Date changed from 1 Oct 2025 to 31 Dec 2026.